Jasper Therapeutics (JSPR) Earnings Date & Reports

Key Takeaways

• Jasper Therapeutics (JSPR) is expected to report results for the third quarter of 2026 (the three months ended September 30, 2026) in early-to-mid November 2026.
• Consensus estimates point to a net loss of roughly $0.06 per share, a significant improvement from the $1.13 loss reported in the same quarter a year earlier.
• Some analysts model between $6 million and $12 million in quarterly revenue, which would mark a notable step up from the $0 recorded in the prior-year period.
• Investors will focus on briquilimab clinical progress, research and development (R&D) spending, and the company's cash runway.
• Jasper's most recent report (Q2 2026) showed a loss of $0.10 per share, beating consensus of about $0.27, yet shares have remained under pressure.
• For more detail on the company's Major News, Today's Price Move, Price Targets, and Forecast, explore the dedicated Tickeron pages.
• Explore Trending AI Robots for automated trading strategies and real-time market insights.

Earnings Context and Why It Matters

Jasper Therapeutics is a clinical-stage biotechnology company whose lead candidate, briquilimab, targets the CD117 (c-Kit) receptor to address mast cell-driven diseases such as chronic spontaneous urticaria (CSU, a form of chronic hives) and chronic inducible urticaria (CIndU). Because the company does not yet generate product revenue, its quarterly updates are less about sales and more about pipeline execution, clinical data timing, and cash management. This report matters because it will show how quickly Jasper is spending on its trials and how far its balance sheet can carry its programs toward the next catalysts. For investors, the release serves as a checkpoint on both near-term milestone timing and the company's potential need for additional capital.

Earnings Expectations

For the third quarter of 2026, Wall Street's consensus centers on a net loss of roughly $0.06 per share, with individual estimates ranging near $0.06 to $0.08. That compares with a loss of $1.13 per share in the year-ago quarter, reflecting a substantially narrower expected loss. On the revenue line, a subset of analysts models between roughly $6 million and $12 million, whereas Jasper historically reports no product revenue, so any collaboration or licensing recognition would be a meaningful signal to watch.

For context, Jasper's last report (the second quarter of 2026, released in August) delivered a loss of $0.10 per share, beating consensus of about $0.27. The company has beaten EPS (earnings per share) expectations in several recent quarters, though its shares have still trended lower. Key metrics investors will scrutinize include R&D expense, cash and equivalents on hand, and any commentary on the durability of the company's runway.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF (exchange-traded fund) discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener can help identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. For investors tracking clinical-stage names like JSPR, it offers a structured way to monitor momentum and setup changes across the biotechnology sector.

Market Reaction and Investor Sentiment

Sentiment heading into the Q3 2026 report remains cautious. Jasper's shares have traded near $0.50 in recent weeks, well below their levels of a year earlier, as development-stage risk and dilution concerns weigh on the stock. The company's prior earnings release in August 2026 was followed by continued selling pressure, and data trackers note a negative post-earnings drift since that report. Investors are not merely trading the bottom-line loss; they are positioning around clinical catalysts, financing needs, and whether the company can demonstrate progress on briquilimab's path toward late-stage development. Key risks heading into the print include any indication of higher-than-expected cash burn, a delayed catalyst timeline, or the absence of revenue recognition that some analysts have begun to model.

Forward Outlook and Key Factors to Monitor

Looking beyond the upcoming print, investors should track several forward-looking themes. First is briquilimab's clinical progress in chronic urticaria and lower-risk myelodysplastic syndromes (MDS, a group of blood disorders), where data readouts and regulatory interactions will shape the company's trajectory. Any updated timing for pivotal studies or discussions with regulators would be a significant catalyst.

Second is the balance sheet. As a pre-revenue company, Jasper's cash runway and R&D spending trends will be closely watched. If the report signals an accelerated burn rate, attention may shift to the timing and terms of potential future financings, which can affect existing shareholders.

Third is revenue recognition. If analysts' early revenue estimates reflect a new collaboration or partnership, confirmation of those economics could change how the market values the company. Finally, investors should watch broader sentiment toward small-cap and clinical-stage biotechnology stocks, which can amplify price moves around earnings regardless of the company's fundamentals.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations